Successful Rechallenge of Hepaftocellular Carcinoma with Atezolizumab and Bevacizumab Following Disease Progression
Systemic therapies to treat Hepatocellular Carcinoma (HCC), a cancer with traditionally poor prognosis, have greatly advanced in the last five years with the advent of immunotherapies. The immune checkpoint inhibitor atezolizumab and anti-angiogen ic agent bevacizumab combination therapy is now recommend ed as first line treatment for unresectable HCC. Bevacizumab is associated with an increased […]